安罗替尼联合PD-1抗体用于晚期非小细胞肺癌三线及以上治疗的疗效与安全性

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.

作者信息

Zhai Chongya, Zhang Xiaoling, Ren Lulu, You Liangkun, Pan Qin, Pan Hongming, Han Weidong

机构信息

Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

出版信息

Front Oncol. 2021 Feb 17;10:619010. doi: 10.3389/fonc.2020.619010. eCollection 2020.

DOI:10.3389/fonc.2020.619010

PMID:33680942

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927598/

Abstract

BACKGROUND

Both anlotinib and programmed death 1 (PD-1) monoclonal antibody (mAb) have been approved for the third line treatment of metastatic non-small cell lung cancer (NSCLC). However, the combination of these two standard therapies has not been investigated in third-line or further-line treatment of patients with advanced NSCLC.

METHODS

We reviewed 22 patients with NSCLC who received anlotinib combined with PD-1 mAb therapy from July 2018 to October 2019 at Sir Run Run Shaw Hospital. Based on the baseline characteristics, PD-L1 expression and EGFR mutation status, we retrospectively analyzed the efficacy and safety of this combination therapy by RESIST 1.1 and CTCAE 5.0.

RESULTS

The combination treatment of anlotinib and PD-1 mAb in 22 NSCLC patients gained a median PFS of 6.8 months and a median OS of 17.3 months. The disease control rate (DCR) was 90.9%, and the objective response rate (ORR) was 36.4%, where 1 (4.6%) patient achieved complete response (CR) and 7 (31.8%) patients achieved partial response (PR). The median time to response was 3.9 months, and the median duration of the response was 6.8 months. The common grades 1-2 adverse events were fatigue 10/22 (45.5%), decreased appetite 9/22 (40.9%), hypertension 10/22 (45.5%); the common grades 3-4 adverse events were hypertension 2/22 (9.1%) and mouth ulceration 2/22 (9.1%).

CONCLUSION

Anlotinib combined with PD-1 mAb showed promising efficacy in third-line or further-line treatment of NSCLC, and its adverse effects is tolerable.

摘要

背景

安罗替尼和程序性死亡受体1（PD-1）单克隆抗体（mAb）均已获批用于转移性非小细胞肺癌（NSCLC）的三线治疗。然而，这两种标准疗法的联合应用在晚期NSCLC患者的三线或更后线治疗中尚未得到研究。

方法

我们回顾了2018年7月至2019年10月在浙江大学医学院附属邵逸夫医院接受安罗替尼联合PD-1 mAb治疗的22例NSCLC患者。根据基线特征、PD-L1表达和EGFR突变状态，我们采用RESIST 1.1和CTCAE 5.0对该联合治疗的疗效和安全性进行了回顾性分析。

结果

22例NSCLC患者接受安罗替尼联合PD-1 mAb治疗，中位无进展生存期（PFS）为6.8个月，中位总生存期（OS）为17.3个月。疾病控制率（DCR）为90.9%，客观缓解率（ORR）为36.4%，其中1例（4.6%）患者达到完全缓解（CR），7例（31.8%）患者达到部分缓解（PR）。中位缓解时间为3.9个月，中位缓解持续时间为6.8个月。常见的1-2级不良事件为疲劳10/22（45.5%）、食欲下降9/22（40.9%）、高血压10/22（45.5%）；常见的3-4级不良事件为高血压2/22（9.1%）和口腔溃疡2/22（9.1%）。